Navigation Links
GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
Date:12/11/2007

ater than 70 years of age, and demonstrated the safety profile of rosiglitazone to be consistent with the control medicine (sulfonylurea).

Importantly, the results of this study do not reproduce what is already known about the risk of CHF in TZD users. TZDs can cause fluid retention which can lead to or exacerbate heart failure. TZDs also have a similar increased risk of CHF. Yet, in this analysis, pioglitazone is not associated with an increased risk of CHF (Adjusted RR of 0.91 (95% CI = 0.52-1.59) whereas rosiglitazone is associated with 2 fold-increased risk of CHF (Adjusted RR = 1.98 and 95% CI=1.44-2.72) compared to oral anti-diabetic combination therapy. This is inconsistent with the product labeling.

Moreover, the authors of this retrospective analysis fail to acknowledge the findings of large epidemiological studies, encompassing over 1.3 million patients with type 2 diabetes, as well as other similar studies presented during the recent FDA Advisory Committee meeting. These studies have investigated whether use of rosiglitazone in the real world setting is associated with an increase in myocardial infarction or coronary revascularization. The majority of these studies show that rosiglitazone is not associated with an increased risk of myocardial infarction compared to other anti-diabetic agents.

GSK cites the following as examples of the limitations of this retrospective analysis:

-- As the authors state, patients on TZDs in their analysis may represent

an older, select group of patients with advanced diabetes and therefore

higher baseline risk for cardiovascular disease.

-- The ODB database is composed of a select group of patients.

Rosiglitazone is only prescribed for those patients who fail

treatment on metformin and sulfonylurea, or for whom sulfonylurea or

metformin are contraindicated. The rosiglitazone patients are

therefore ones with higher
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
8. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
9. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
10. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Axovant Sciences Ltd. (NYSE:  AXON), a leading ... announced upcoming presentations at three investor conferences: , ... Healthcare Conference in New York at ... at 2:00 PM at the BioCentury NewsMakers Conference in ... & Conference Center , Thursday, September 17 at 9:30 ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 /PRNewswire/ ... has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. ... the pharmaceutical and biotechnology industries is anticipated. ... of drug development - from formulations for ...
(Date:9/2/2015)... ARBOR, Mich. and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... NSF International, a leading provider of regulatory compliance, quality systems, analytical ... Avarent LLC, a consulting firm with expertise in medical device products/processes development, ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... and Companies" to their offering. ... variations, development of sequencing technologies, and their applications. ... well as companies developing them. Various applications of ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2
... Program -, LIONVILLE, Pa., Feb. 27 West Pharmaceutical,Services, ... of Directors,approved a second quarter 2008 cash dividend of $0.14 ... to shareholders of record on April 23,2008., The Company ... stock at an average price of $40.23 per share since ...
... Feb. 27 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation ... considered as a supplier of bio-fertilizers,for the vegetable ... hotels,during the 2008 Olympics. Kiwa also announced that ... the Company, would participate in an interview with,WallSt.net ...
... PALO ALTO, Calif., Feb. 27 Telik, Inc.,(Nasdaq: ... or $0.25 per share,for the fourth quarter ended December ... or $0.34 per share, for the comparable period in ... total operating costs and,expenses were $13.5 million, compared with ...
Cached Biology Technology:Beijing 2008 Olympic Games Vegetable Supplier Considering Kiwa as a Supplier of Bio-Fertilizers & Kiwa Announces CEO Interview with WallSt.net 2Beijing 2008 Olympic Games Vegetable Supplier Considering Kiwa as a Supplier of Bio-Fertilizers & Kiwa Announces CEO Interview with WallSt.net 3Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance 2Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance 3Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance 4
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/6/2015)... and TELTOW, Germany , August 6, ... Conference, SensoMotoric Instruments (SMI) shows the world,s ... , based on Epson,s Moverio BT-200 see-through head ... With this new solution, unprecedented quality and efficiency is ... with context-sensitive displays. For the first time, professionals and ...
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... 2011 The world,s largest scientific society picked the perfect venue ... American Chemical Society (ACS) Office of Public Affairs invites your coverage ... for the theme The Chemistry of Air, Space and Water ... in and near Denver ranging from hot air balloon rides, to ...
... Brussels, 25 July 2011 - G protein-coupled receptors ... of approved drugs and many hundreds of drugs currently ... extracellular signals by activating heterotrimeric G proteins (G proteins) ... shape of these proteins determine essential processes, including whether ...
... an astounding evolutionary event occurred: certain bacteria became obliged ... of events that resulted in what is now the ... A recent study by researchers at the University of ... (OSU) provides strong evidence that mitochondria share a common ...
Cached Biology News:News media registration for American Chemical Society National Meeting Denver, Aug. 28-Sept. 1, 2011 2Common drugs initiate a molecular pas de quatre at the surface of the cell membrane 2Common drugs initiate a molecular pas de quatre at the surface of the cell membrane 3Mitochondria share an ancestor with SAR11, a globally significant marine microbe 2
BD Primaria 35 mm Cell Culture Dish with Easy-Grip design, surface-modified polystyrene for enhanced cell culture. (20/sp, 200/ca) Packaging: 20 / sleeve, 500 / case ...
... premium quality recombinant form of Thermus aquaticus ... for a wide range of PCR applications. ... performance, each preparation is extensively tested in ... DNA Polymerase possesses an integral 5′→3′ exonuclease ...
... a direct antibiotic-based selection system for recombinant ... survival, eliminating the need for costly color ... close to 100% accuracy in recombinant selection. ... robot colony picking. This cloning kit can ...
AVOID FREEZE/THAW CYCLES. Recognizes the ~32 kDa DNase IIα chain and the ~40 kDa proenzyme. DNase II causes both DNA condensation and DNA fragmentation. ...
Biology Products: